SynthesisThe British journal of dermatology2016
Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality.
Synthesis in The British journal of dermatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Effectiveness of controlled decompression against conventional decompression methods for the management of severe traumatic brain injury patients: a meta-analysis.European journal of medical research · 2025Pooled it
- Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review.Journal of the American Academy of Dermatology · 2020Pooled it
- Dual immunomodulator therapy with upadacitinib and bimekizumab in severe hidradenitis suppurativa: A case report.JAAD case reports · 2026Article
- Management of penoscrotal hidradenitis: a narrative review.International journal of impotence research · 2025Review
- Inborn Errors of Immunity in Hidradenitis Suppurativa Pathogenesis and Disease Burden.Journal of clinical immunology · 2023Review
- Hidradenitis Suppurativa: Molecular Etiology, Pathophysiology, and Management-A Systematic Review.Current issues in molecular biology · 2023Review
- Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data.Frontiers in medicine · 2023Review
- Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa.The British journal of dermatology · 2022Article
- The Use of Botulinum Toxin in the Management of Hidradenitis Suppurativa: A Systematic Review.Plastic and reconstructive surgery. Global open · 2022Article
- Surgical Management of Hidradenitis Suppurativa: A Narrative Review.The Journal of clinical and aesthetic dermatology · 2022Review
- Review
- [Impact of LAight therapy on hidradenitis suppurativa care].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021Article
- Risk of Hidradenitis Suppurativa Comorbidities Over Time: A Prospective Cohort Study of Danish Blood Donors.Acta dermato-venereologica · 2021Article
- Assessing the compliance of systematic review articles published in leading dermatology journals with the PRISMA statement guidelines: A systematic review.JAAD international · 2020Review
- Inter- and intrarater reliability of Hurley staging for hidradenitis suppurativa.The British journal of dermatology · 2019Article
- North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.Journal of the American Academy of Dermatology · 2019Review
- Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology.Anais brasileiros de dermatologia · 2019Article
- TNF-α inhibitors in the treatment of hidradenitis suppurativa.Therapeutic advances in chronic disease · 2019Review
- Hidradenitis Suppurativa: Causes, Features, and Current Treatments.The Journal of clinical and aesthetic dermatology · 2018Review
- Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data.Dermatology reports · 2018Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than 50 interventions have been used to treat hidradenitis suppurativa (HS), and so therapy decisions can be challenging. Our objective was to summarize and appraise randomized controlled trial (RCT) evidence for HS interventions in adults. Searches were conducted in Medline, Embase, CENTRAL, LILACS, five trials registers and abstracts from eight dermatology conferences until 13 August 2015. Two review authors independently assessed study eligibility, extracted data and assessed methodological quality. Primary outcomes were quality of life and adverse effects of the interventions. Twelve trials, from 1983 to 2015, investigating 15 different interventions met our inclusion criteria. The median trial duration was 16 weeks and the median number of participants was 27. Adalimumab 40 mg weekly improved the Dermatology Life Quality Index (DLQI) by 4·0 points, which equates to the minimal clinically important difference for the scale, compared with placebo (95% confidence interval -6·5 to -1·5 points). Evidence quality was reduced to 'moderate' because the results are based on only a single study. Adalimumab 40 mg every other week was ineffective in a meta-analysis of two studies comprising 124 participants. Infliximab 5 mg kg(-1) improved the DLQI score by 8·4 points after 8 weeks in a moderate-quality study completed by 33 of 38 participants. Etanercept 50 mg twice weekly was ineffective. Inclusion of a gentamicin sponge prior to primary closure did not improve outcomes. Other interventions, including topical and oral antibiotics, were investigated by relatively small studies, preventing treatment recommendations due to imprecision. More, larger RCTs are required to investigate most HS interventions, particularly oral treatments and surgical therapy. Moderate-quality evidence suggests that adalimumab given weekly and infliximab are effective, whereas adalimumab every other week is ineffective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.